Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for Molecular Partners Ag (MOLN) over the last 5 years, with Q3 2025 value amounting to -$1.4 million.

  • Molecular Partners Ag's Depreciation & Amortization (CF) rose 92.76% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 45.62%. This contributed to the annual value of $2.7 million for FY2024, which is 129.58% down from last year.
  • Per Molecular Partners Ag's latest filing, its Depreciation & Amortization (CF) stood at -$1.4 million for Q3 2025, which was up 92.76% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Molecular Partners Ag's Depreciation & Amortization (CF) peaked at $2.8 million during Q4 2021, and registered a low of -$1.4 million during Q3 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $730.0 (2021), whereas its average is $556791.1.
  • Within the past 5 years, the most significant YoY rise in Molecular Partners Ag's Depreciation & Amortization (CF) was 1294.8% (2022), while the steepest drop was 1330.83% (2022).
  • Over the past 5 years, Molecular Partners Ag's Depreciation & Amortization (CF) (Quarter) stood at $2.8 million in 2021, then dropped by 10.89% to $2.5 million in 2022, then increased by 10.06% to $2.7 million in 2023, then decreased by 0.88% to $2.7 million in 2024, then plummeted by 151.04% to -$1.4 million in 2025.
  • Its last three reported values are -$1.4 million in Q3 2025, $1.3 million for Q2 2025, and $613.96 during Q1 2025.